Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free NKTR Stock Alerts

Nektar Therapeutics (NKTR) Financials

Nektar Therapeutics logo
$84.16 -2.73 (-3.14%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$85.46 +1.30 (+1.54%)
As of 05/5/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Nektar Therapeutics

Annual Income Statements for Nektar Therapeutics

This table shows Nektar Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -81 -154 -97 681 -441 -444 -524 -368 -276 -119 -164
Consolidated Net Income / (Loss)		 -81 -154 -97 681 -441 -444 -524 -368 -276 -119 -164
Net Income / (Loss) Continuing Operations		 -81 -154 -97 681 -441 -444 -524 -368 -276 -119 -164
Total Pre-Tax Income 		-81 -153 -96 683 -440 -444 -523 -365 -276 -119 -155
Total Operating Income		 -29 -113 -60 688 -440 -425 -446 -376 -264 -105 -140
Total Gross Profit		 197 135 277 1,169 93 133 77 70 56 68 55
Total Revenue		 231 165 308 1,193 115 153 102 92 90 98 55
Operating Revenue		 231 165 308 1,193 115 153 102 92 90 98 55
Total Cost of Revenue		 34 30 31 24 21 19 25 22 34 31 0.00
Operating Cost of Revenue		 34 30 31 24 21 19 25 22 34 31 0.00
Total Operating Expenses		 226 248 337 481 533 559 523 447 320 173 195
Selling, General & Admin Expense		 43 44 52 81 99 105 123 92 77 77 69
Research & Development Expense		 183 204 268 400 435 409 400 218 114 121 117
Other Operating Expenses / (Income)		 - - - - - - - - 0.00 -40 0.00
Restructuring Charge		 - - - - - - 0.00 136 52 16 9.33
Total Other Income / (Expense), net		 -51 -40 -36 -5.21 -0.02 -19 -77 11 -13 -14 -15
Interest Expense		 53 42 41 43 46 37 47 29 25 28 26
Interest & Investment Income		 - - - - - - 2.73 6.78 19 15 10
Other Income / (Expense), net		 1.68 2.39 4.52 38 46 18 -33 33 -6.25 -0.39 0.36
Income Tax Expense		 0.51 0.88 0.62 1.41 0.61 0.49 0.56 3.22 -0.20 -0.24 -0.14
Other Gains / (Losses), net		 - - - - - - - - - 0.00 -8.73
Basic Earnings per Share		 ($0.61) ($1.10) ($0.62) $4.02 ($2.52) ($2.49) ($2.86) ($1.97) ($1.45) ($8.68) ($9.73)
Weighted Average Basic Shares Outstanding		 132.46M 139.60M 155.95M 169.60M 174.99M 178.58M 183.30M 187.14M 190.00M 13.71M 16.87M
Diluted Earnings per Share		 ($0.61) ($1.10) ($0.62) $3.78 ($2.52) ($2.49) ($2.86) ($1.97) ($1.45) ($8.68) ($9.73)
Weighted Average Diluted Shares Outstanding		 132.46M 139.60M 155.95M 180.12M 174.99M 178.58M 183.30M 187.14M 190.00M 13.71M 16.87M
Weighted Average Basic & Diluted Shares Outstanding		 132.46M 139.60M 156M 169.50M 177.56M 182.18M 186.27M 189.24M 183.62M 186.10M 28.69M

Quarterly Income Statements for Nektar Therapeutics

This table shows Nektar Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -51 -46 -42 -37 -52 -37 7.26 -51 -42 -36 -36
Consolidated Net Income / (Loss)		 -51 -46 -42 -37 -52 -37 7.26 -51 -42 -36 -36
Net Income / (Loss) Continuing Operations		 -51 -46 -42 -37 -52 -37 7.26 -51 -42 -36 -36
Total Pre-Tax Income 		-51 -46 -42 -37 -52 -37 7.00 -46 -39 -35 -35
Total Operating Income		 -51 -45 -34 -35 -50 -34 14 -45 -36 -32 -28
Total Gross Profit		 14 12 17 13 14 20 21 10 11 12 22
Total Revenue		 20 24 24 22 23 24 29 10 11 12 22
Operating Revenue		 20 24 24 22 23 24 29 10 11 12 22
Total Operating Expenses		 64 57 50 49 64 54 6.85 55 47 43 49
Selling, General & Admin Expense		 18 21 17 20 21 19 17 24 17 16 11
Research & Development Expense		 30 24 30 27 30 35 29 30 30 27 30
Restructuring Charge		 17 11 2.85 0.98 13 0.05 1.36 0.17 0.45 0.14 8.58
Total Other Income / (Expense), net		 -0.57 -1.03 -8.60 -1.41 -2.54 -2.70 -7.35 -1.83 -3.17 -3.35 -7.04
Interest Expense		 6.15 5.91 6.87 5.53 6.41 6.02 10 4.97 5.39 6.05 9.77
Interest & Investment Income		 4.85 5.21 4.62 4.22 3.90 3.44 2.94 2.87 1.97 2.82 2.78
Other Income / (Expense), net		 0.74 -0.34 -6.35 -0.10 -0.04 -0.12 -0.14 0.27 0.26 -0.12 -0.04
Income Tax Expense		 -0.05 -0.06 -0.03 -0.04 0.05 0.01 -0.26 0.05 -0.19 -0.03 0.03
Other Gains / (Losses), net		 - - - 0.00 0.00 0.00 - -4.46 -2.39 -0.53 -1.35
Basic Earnings per Share		 ($0.27) ($0.24) ($0.21) ($0.19) ($3.76) ($2.66) $0.04 ($0.24) ($2.95) ($1.87) ($2.14)
Weighted Average Basic Shares Outstanding		 189.66M 190.41M 190.00M 194.75M 13.92M 13.95M 205.66M 210.92M 14.09M 18.95M 16.87M
Diluted Earnings per Share		 ($0.27) ($0.24) ($0.21) ($0.19) ($3.76) ($2.66) $0.04 ($0.24) ($2.95) ($1.87) ($2.14)
Weighted Average Diluted Shares Outstanding		 189.66M 190.41M 190.00M 194.75M 13.92M 13.95M 205.66M 210.92M 14.09M 18.95M 16.87M
Basic & Diluted Earnings per Share		 - - - - - - - - - - ($2.14)
Weighted Average Basic & Diluted Shares Outstanding		 190.12M 190.77M 183.62M 183.62M 184.08M 184.46M 186.10M 186.10M 19.02M 20.34M 28.69M

Annual Cash Flow Statements for Nektar Therapeutics

This table details how cash moves in and out of Nektar Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 43 4.07 -55 190 -99 103 -174 63 -53 8.98 -29
Net Cash From Operating Activities		 -73 -117 -80 718 -329 -313 -413 -304 -193 -176 -209
Net Cash From Continuing Operating Activities		 -73 -117 -80 718 -329 -313 -413 -304 -193 -176 -209
Net Income / (Loss) Continuing Operations		 -81 -154 -97 681 -441 -444 -524 -368 -276 -119 -164
Consolidated Net Income / (Loss)		 -81 -154 -97 681 -441 -444 -524 -368 -276 -119 -164
Depreciation Expense		 13 15 15 11 13 14 14 13 7.82 4.39 1.03
Amortization Expense		 - - - - -11 3.94 6.73 -2.44 -15 -9.25 -5.51
Non-Cash Adjustments To Reconcile Net Income		 30 13 39 65 102 99 116 48 102 -59 -18
Changes in Operating Assets and Liabilities, net		 -35 7.93 -38 -39 8.60 14 -25 5.88 -11 6.67 -22
Net Cash From Investing Activities		 -14 -82 -29 -1,380 207 496 203 366 140 143 -1.20
Net Cash From Continuing Investing Activities		 -14 -82 -29 -1,380 207 496 203 366 140 143 -1.20
Purchase of Property, Plant & Equipment		 -11 -6.39 -9.68 -14 -26 -7.26 -15 -5.68 -0.87 -1.47 -0.17
Purchase of Investments		 -298 -335 -404 -2,271 -1,381 -988 -961 -468 -512 -262 -285
Sale and/or Maturity of Investments		 269 259 385 903 1,614 1,491 1,178 826 651 340 285
Other Investing Activities, net		 25 - - - - - - - 0.00 65 -0.70
Net Cash From Financing Activities		 131 204 54 852 23 -80 36 1.51 0.03 42 181
Net Cash From Continuing Financing Activities		 131 204 54 852 23 -80 36 1.51 0.03 42 181
Repurchase of Common Equity		 - - - - - - - - 0.00 -3.00 -1.15
Issuance of Common Equity		 32 210 60 852 23 23 33 0.76 0.03 30 182
Other Financing Activities, net		 - - - 0.00 0.00 146 3.00 0.75 0.00 15 0.00
Effect of Exchange Rate Changes		 -0.16 - -0.05 - -0.10 0.02 -0.09 -0.33 0.06 -0.00 0.01
Cash Income Taxes Paid		 0.86 0.76 0.56 0.62 0.56 0.54 0.33 0.27 2.66 0.08 -0.20

Quarterly Cash Flow Statements for Nektar Therapeutics

This table details how cash moves in and out of Nektar Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 -26 14 -30 13 -21 2.17 14 -5.36 4.09 -1.96 -26
Net Cash From Operating Activities		 -52 -42 -47 -48 -38 -44 -46 -49 -46 -49 -65
Net Cash From Continuing Operating Activities		 -52 -42 -47 -48 -38 -44 -46 -49 -46 -49 -65
Net Income / (Loss) Continuing Operations		 -51 -46 -42 -37 -52 -37 7.26 -51 -42 -36 -36
Consolidated Net Income / (Loss)		 -51 -46 -42 -37 -52 -37 7.26 -51 -42 -36 -36
Depreciation Expense		 2.17 1.70 1.65 1.61 1.46 0.99 0.33 0.43 0.21 0.20 0.19
Amortization Expense		 - - - -3.06 -2.58 -2.06 - -1.32 -0.87 -1.43 -1.89
Non-Cash Adjustments To Reconcile Net Income		 4.89 2.91 8.48 -5.93 3.69 -10 -38 1.06 -3.68 -5.66 -9.81
Changes in Operating Assets and Liabilities, net		 -7.46 -0.89 -0.25 -3.70 12 4.49 -6.22 1.67 0.19 -6.34 -17
Net Cash From Investing Activities		 25 56 17 19 17 46 60 44 50 -95 0.37
Net Cash From Continuing Investing Activities		 25 56 17 19 17 46 60 44 50 -95 0.37
Purchase of Property, Plant & Equipment		 -0.16 -0.03 -0.24 -0.16 -0.19 -0.67 -0.46 -0.00 -0.04 -0.11 -0.02
Purchase of Investments		 -143 -123 -139 -105 -68 -18 -70 -25 -19 -150 -92
Sale and/or Maturity of Investments		 168 178 156 124 86 65 65 69 69 55 92
Net Cash From Financing Activities		 0.02 - 0.01 42 0.02 0.01 0.08 0.01 0.21 142 39
Net Cash From Continuing Financing Activities		 0.02 - 0.01 42 0.02 0.01 0.08 0.01 0.21 142 39
Issuance of Common Equity		 0.02 - 0.01 30 0.02 0.01 0.08 0.01 0.21 143 39

Annual Balance Sheets for Nektar Therapeutics

This table presents Nektar Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 499 569 509 2,150 1,977 1,539 1,117 711 398 304 280
Total Current Assets		 350 426 327 1,438 1,422 1,138 796 546 331 261 266
Cash & Equivalents		 56 60 4.76 195 96 199 25 88 35 44 15
Short-Term Investments		 253 329 291 1,140 1,228 863 709 417 268 211 231
Other Current Assets		 9.81 10 15 48 47 22 23 16 9.78 6.07 21
Plant, Property, & Equipment, net		 71 66 47 49 66 60 61 32 19 3.41 2.06
Total Noncurrent Assets		 77 77 135 664 490 341 261 132 48 39 12
Long-Term Investments		 - 0.00 57 583 279 137 65 0.00 26 26 3.49
Other Noncurrent Operating Assets		 0.75 0.82 0.99 4.24 135 128 120 56 23 13 8.59
Total Liabilities & Shareholders' Equity		 499 569 509 2,150 1,977 1,539 1,117 711 398 304 280
Total Liabilities		 492 481 421 433 572 461 438 344 267 243 191
Total Current Liabilities		 61 72 56 82 354 116 85 68 51 61 54
Accounts Payable		 2.36 2.82 4.78 5.85 19 22 9.75 13 9.85 12 11
Accrued Expenses		 12 13 20 48 52 65 42 37 22 30 22
Other Current Liabilities		 10 20 0.45 0.49 13 - 17 19 - 20 20
Total Noncurrent Liabilities		 431 409 365 351 218 346 352 276 216 182 137
Other Noncurrent Operating Liabilities		 126 113 101 93 216 346 352 276 216 182 137
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 6.43 88 88 1,718 1,405 1,077 680 367 131 61 90
Total Preferred & Common Equity		 6.43 88 88 1,718 1,405 1,077 680 367 131 61 90
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 6.43 88 88 1,718 1,405 1,077 680 367 131 61 90
Common Stock		 1,876 2,111 2,208 3,148 3,271 3,389 3,517 3,575 3,608 3,660 3,850
Retained Earnings		 -1,867 -2,021 -2,118 -1,424 -1,865 -2,309 -2,833 -3,201 -3,477 -3,596 -3,760
Treasury Stock		 - - - - - - - - 0.00 -3.00 0.00
Accumulated Other Comprehensive Income / (Loss)		 -2.17 -2.36 -2.11 -6.32 -1.01 -2.30 -4.16 -6.91 0.08 0.06 0.02

Quarterly Balance Sheets for Nektar Therapeutics

This table presents Nektar Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 494 442 396 343 308 256 208 301
Total Current Assets		 441 399 320 295 286 230 187 281
Cash & Equivalents		 51 65 49 28 30 39 43 41
Short-Term Investments		 359 308 241 243 214 180 133 229
Other Current Assets		 9.60 9.03 11 8.29 8.93 11 11 11
Plant, Property, & Equipment, net		 23 20 17 15 3.60 3.16 2.99 2.83
Total Noncurrent Assets		 31 23 59 33 18 23 18 17
Long-Term Investments		 - - 37 19 4.54 9.78 5.37 4.84
Other Noncurrent Operating Assets		 31 23 22 14 13 13 13 12
Total Liabilities & Shareholders' Equity		 494 442 396 343 308 256 208 301
Total Liabilities		 297 283 269 264 259 243 232 216
Total Current Liabilities		 51 52 52 57 68 71 71 66
Short-Term Debt		 - - - - - 22 - 22
Accounts Payable		 2.62 3.29 8.76 6.48 8.58 18 14 16
Accrued Expenses		 29 30 24 30 32 31 35 29
Total Noncurrent Liabilities		 247 231 217 206 191 172 160 150
Other Noncurrent Operating Liabilities		 247 231 217 206 191 172 160 150
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 197 159 127 80 49 14 -24 85
Total Preferred & Common Equity		 197 159 127 80 49 14 -24 85
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 197 159 127 80 49 14 -24 85
Common Stock		 3,593 3,601 3,644 3,650 3,655 3,664 3,667 3,809
Retained Earnings		 -3,389 -3,435 -3,514 -3,566 -3,603 -3,647 -3,689 -3,724
Treasury Stock		 - - -3.00 -3.00 -3.00 -3.00 -3.00 0.00
Accumulated Other Comprehensive Income / (Loss)		 -6.45 -6.35 -0.40 -0.49 0.36 0.04 -0.01 0.06

Annual Metrics And Ratios for Nektar Therapeutics

This table displays calculated financial ratios and metrics derived from Nektar Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 133,451,372.00 152,835,294.00 157,467,703.00 173,085,231.00 175,922,206.00 179,398,666.00 184,557,124.00 187,954,482.00 190,770,566.00 - 20,341,589.00
DEI Adjusted Shares Outstanding		 8,896,758.00 10,189,020.00 10,497,847.00 11,539,015.00 11,728,147.00 11,959,911.00 12,303,808.00 12,530,299.00 12,718,038.00 - 20,341,589.00
DEI Earnings Per Adjusted Shares Outstanding		 -9.12 -15.07 -9.21 59.04 -37.57 -37.16 -42.58 -29.38 -21.71 - -8.07
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -21 -79 -42 687 -308 -298 -312 -263 -185 -74 -98
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -122.85% -121.24% -109.17%
Earnings before Interest and Taxes (EBIT)		 -28 -110 -55 726 -394 -407 -479 -343 -270 -106 -140
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -95 -40 736 -392 -389 -458 -332 -277 -110 -144
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -56 -76 -79 620 -312 -136 -300 -244 -144 -32 -159
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -51 -53 -16 50 54 -107 -119 -138 -179 -221 -159
Increase / (Decrease) in Invested Capital		 35 -2.53 37 66 3.82 -162 -12 -19 -41 -41 61
Book Value per Share		 $0.05 $0.58 $0.56 $9.92 $7.99 $6.01 $3.68 $1.95 $0.69 $0.33 $4.42
Tangible Book Value per Share		 ($0.53) $0.08 $0.07 $9.48 $7.55 $5.58 $3.27 $1.54 $0.69 $0.33 $4.42
Total Capital		 254 332 333 1,965 1,658 1,091 680 367 150 61 90
Total Debt		 248 243 245 247 253 14 0.00 0.00 19 0.00 0.00
Total Long-Term Debt		 243 243 245 247 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -61 -146 -108 -1,671 -1,351 -1,185 -799 -505 -310 -281 -249
Capital Expenditures (CapEx)		 11 6.39 9.68 12 26 7.26 15 -7.52 -0.38 1.47 0.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -35 -25 20 -4.31 -26 -24 -27 -4.93 -55 -33
Debt-free Net Working Capital (DFNWC)		 294 354 271 1,356 1,321 1,036 710 478 299 200 213
Net Working Capital (NWC)		 289 354 271 1,356 1,068 1,022 710 478 279 200 213
Net Nonoperating Expense (NNE)		 61 75 55 5.20 133 147 212 105 91 45 66
Net Nonoperating Obligations (NNO)		 -57 -141 -104 -1,667 -1,351 -1,185 -799 -505 -310 -281 -249
Total Depreciation and Amortization (D&A)		 13 15 15 11 1.76 18 21 11 -7.04 -4.85 -4.49
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.61) ($1.10) ($0.62) $4.02 ($2.52) ($2.49) ($2.86) ($1.97) ($1.45) ($0.58) ($9.73)
Adjusted Weighted Average Basic Shares Outstanding		 135.94M 153.83M 160.92M 169.60M 174.99M 178.58M 183.30M 187.14M 190.00M 205.66M 16.87M
Adjusted Diluted Earnings per Share		 ($0.61) ($1.10) ($0.62) $3.78 ($2.52) ($2.49) ($2.86) ($1.97) ($1.45) ($0.58) ($9.73)
Adjusted Weighted Average Diluted Shares Outstanding		 135.94M 153.83M 160.92M 180.12M 174.99M 178.58M 183.30M 187.14M 190.00M 205.66M 16.87M
Adjusted Basic & Diluted Earnings per Share		 ($0.61) ($1.10) ($0.62) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 132.46M 139.60M 155.95M 174.10M 177.56M 182.18M 186.27M 189.24M 183.62M 186.10M 28.69M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -79 -31 687 -308 -266 -312 -168 -95 -63 -92
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Nektar Therapeutics

This table displays calculated financial ratios and metrics derived from Nektar Therapeutics' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 189,235,157.00 190,118,673.00 190,770,566.00 183,617,817.00 183,624,620.00 184,079,479.00 - 186,103,588.00 186,103,588.00 19,018,573.00 20,341,589.00
DEI Adjusted Shares Outstanding		 12,615,677.00 12,674,578.00 12,718,038.00 12,241,188.00 12,241,641.00 12,271,965.00 - 12,406,906.00 12,406,906.00 19,018,573.00 20,341,589.00
DEI Earnings Per Adjusted Shares Outstanding		 -4.05 -3.62 -3.31 -3.01 -4.28 -3.02 - -4.10 -3.35 -1.87 -1.77
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -35 -31 -23 -25 -35 -24 15 -31 -25 -22 -19
Return On Investment Capital (ROIC_SIMPLE)		 - - -15.61% -19.57% -43.72% -49.18% 24.50% -87.62% 104.75% -20.67% -21.56%
Earnings before Interest and Taxes (EBIT)		 -50 -45 -40 -36 -50 -34 14 -44 -36 -32 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -48 -44 -38 -37 -51 -36 15 -45 -37 -33 -29
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 7.54 48 17 -41 -36 -9.26 56 -38 -31 -82 -81
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -212 -213 -179 -199 -211 -228 -221 -193 -205 -168 -159
Increase / (Decrease) in Invested Capital		 -43 -79 -41 17 1.52 -15 -41 6.48 5.47 60 61
Book Value per Share		 $1.04 $0.84 $0.69 $0.69 $0.43 $0.27 $0.33 $0.07 ($0.13) $4.47 $4.42
Tangible Book Value per Share		 $1.04 $0.84 $0.69 $0.69 $0.43 $0.27 $0.33 $0.07 ($0.13) $4.47 $4.42
Total Capital		 197 159 150 127 80 49 61 36 -24 107 90
Total Debt		 0.00 0.00 19 0.00 0.00 0.00 0.00 22 0.00 22 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -409 -373 -310 -326 -291 -249 -281 -207 -181 -253 -249
Capital Expenditures (CapEx)		 0.16 0.03 0.24 0.16 0.19 0.67 0.46 0.00 0.04 0.11 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -19 -26 -4.93 -22 -33 -26 -55 -38 -61 -33 -33
Debt-free Net Working Capital (DFNWC)		 390 347 299 267 238 219 200 181 115 237 213
Net Working Capital (NWC)		 390 347 279 267 238 219 200 159 115 215 213
Net Nonoperating Expense (NNE)		 16 14 19 12 18 13 7.62 20 16 13 17
Net Nonoperating Obligations (NNO)		 -409 -373 -310 -326 -291 -277 -281 -207 -181 -253 -249
Total Depreciation and Amortization (D&A)		 2.17 1.70 1.65 -1.46 -1.13 -1.07 0.33 -0.90 -0.66 -1.24 -1.70
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.27) ($0.24) ($0.21) ($0.19) ($3.75) ($2.70) $0.04 ($0.24) ($2.95) ($1.87) ($2.14)
Adjusted Weighted Average Basic Shares Outstanding		 189.66M 190.41M 190.00M 194.75M 13.92M 13.95M 205.66M 210.92M 14.09M 18.95M 16.87M
Adjusted Diluted Earnings per Share		 ($0.27) ($0.24) ($0.21) ($0.19) ($3.75) ($2.70) $0.04 ($0.24) ($2.95) ($1.87) ($2.14)
Adjusted Weighted Average Diluted Shares Outstanding		 189.66M 190.41M 190.00M 194.75M 13.92M 13.95M 205.66M 210.92M 14.09M 18.95M 16.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($2.14)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 190.12M 190.77M 183.62M 183.62M 12.27M 12.30M 186.10M 186.10M 19.02M 20.34M 28.69M
Normalized Net Operating Profit after Tax (NOPAT)		 -24 -23 -21 -24 -26 -24 11 -31 -25 -22 -13
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Nektar Therapeutics (NKTR) continues to show meaningful regulatory and liquidity activity in its quarterly results, with losses persisting but funding secured through equity raises. Cash flow remains volatile, driven more by financing activities than ongoing operations. Below are the key trends from the latest four years of quarterly data, focusing on what could matter to retail investors.

  • Equity financing boosted liquidity in 2025, with large common stock issuances driving net cash from financing activities: about $141.7 million in Q3 2025 and about $38.7 million in Q4 2025.
  • Strong liquidity from cash plus investments tops roughly $270 million in Q3 2025 (cash around $41.0 million and short-term investments about $229.2 million), helping fund R&D and operations without immediate debt pressure.
  • Gross margins appear robust in recent quarters, with gross profit roughly equal to revenue in several periods (e.g., Q3 2025 and Q4 2025 show Total Gross Profit matching Operating Revenue), indicating no direct cost of revenue in these periods.
  • Q4 2025 revenue rose to about $21.81 million, roughly doubling Q3 2025’s $11.79 million and indicating a topline uptick compared with earlier 2025 quarters.
  • Operating expenses remain elevated (e.g., RD about $29.7 million and SG&A around $11.2 million in Q4 2025), contributing to ongoing net losses but consistent with a high-R&D biotech profile.
  • Some quarters show sizable positive cash inflows from investing activities (notably from sale/maturity of investments), which can mask ongoing operating losses and may reflect non-recurring liquidity events.
  • Net income is negative in every reported quarter, with losses in the mid-to-high $30s to $50 million range in 2025 (e.g., Q4 -$36.1 million; Q3 -$35.5 million; Q2 -$41.6 million; Q1 -$50.9 million).
  • Operating cash flow is negative across 2025 quarters, signaling ongoing cash burn from core operations (Q4 -$64.96 million; Q3 -$48.76 million; Q2 -$45.74 million; Q1 -$49.05 million).
  • Total operating expenses in Q4 2025 were high at about $49.47 million, driven by RD and SGA plus restructuring, underscoring ongoing cost pressures.
  • Some balance-sheet dynamics suggest a structural reliance on financing activities to fund operations rather than consistent profitability, given heavy equity issuance and persistent losses.
05/05/26 11:23 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Nektar Therapeutics' Financials

When does Nektar Therapeutics' financial year end?

According to the most recent income statement we have on file, Nektar Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Nektar Therapeutics' net income changed over the last 10 years?

Nektar Therapeutics' net income appears to be on an upward trend, with a most recent value of -$164.08 million in 2025, rising from -$81.18 million in 2015. The previous period was -$118.96 million in 2024. Check out Nektar Therapeutics' forecast to explore projected trends and price targets.

What is Nektar Therapeutics' operating income?
Nektar Therapeutics' total operating income in 2025 was -$140.10 million, based on the following breakdown:
  • Total Gross Profit: $55.23 million
  • Total Operating Expenses: $195.33 million
How has Nektar Therapeutics' revenue changed over the last 10 years?

Over the last 10 years, Nektar Therapeutics' total revenue changed from $230.78 million in 2015 to $55.23 million in 2025, a change of -76.1%.

How much debt does Nektar Therapeutics have?

Nektar Therapeutics' total liabilities were at $190.57 million at the end of 2025, a 21.6% decrease from 2024, and a 61.3% decrease since 2015.

How much cash does Nektar Therapeutics have?

In the past 10 years, Nektar Therapeutics' cash and equivalents has ranged from $4.76 million in 2017 to $198.96 million in 2020, and is currently $15.12 million as of their latest financial filing in 2025.

How has Nektar Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Nektar Therapeutics' book value per share changed from 0.05 in 2015 to 4.42 in 2025, a change of 9,062.2%.


Related Companies

Financial statements for NASDAQ:NKTR last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
A U.S. Resource Gap Is a National Issue - and Opportunity
America still does not domestically produce one mineral tied to batteries, energy storage, and national defens...
i2i Marketing Group, LLC | Sponsoredtc pixel